Calprotectin Independently Predicts Relapse in Treated RA
By LabMedica International staff writers Posted on 14 Jan 2019 |
Image: The Calprolab enzyme-linked immunosorbent assay (ELISA ALP) test kit for calprotectin estimation (Photo courtesy of Calpro).
Calprotectin is a biomarker of disease activity in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) and predicts relapse in juvenile idiopathic arthritis. Higher drug trough serum levels are associated with a good response in patients treated with tumor necrosis factor inhibitors (TNFi).
Biological therapies have dramatically improved the management and prognosis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Remission or low disease activity is possible in an increasing number of patients. Nevertheless, persistent remission is more difficult to achieve since disease relapses are common.
Scientists from the University of Barcelona (Barcelona, Spain) carried out a longitudinal, prospective, one-year single-center study of 103 patients (47 RA, 56 PsA) receiving TNFi in remission or with low disease activity. All patients underwent clinical assessment at baseline and at 4, 8, and 12 months, including 28-joint swollen and tender joint counts (28-SJC and 28-TJC, respectively), physician and patient global assessment with visual analogue scales (0–100 mm), erythrocyte sedimentation rate (ESR; mm), and C-reactive protein (CRP; mg/dL).
Calprotectin serum levels, TNFi trough serum levels, and antidrug antibodies were determined at baseline (visit 0) and during disease relapse using an enzyme-linked immunosorbent assay (ELISA) test kit Calprolab, calprotectin ELISA (ALP), and Promonitor, respectively. To reduce variations in calprotectin determinations, the whole procedure was performed in a Triturus autoanalyzer. Additionally, serum samples were collected at 4, 8, and 12 months of follow-up to assess longitudinal changes in drug trough serum levels.
The scientists reported that 95 patients completed one year of follow-up, of whom 12 experienced a relapse. At baseline, relapsers had higher calprotectin levels, lower TNFi TSL, and higher power Doppler (PD) activity than nonrelapsers. Receiver operating characteristic (ROC) analysis showed calprotectin fully predicted relapse (area under the curve (AUC) = 1.00). The cut-off levels determined by ROC analysis for the optimal prediction of relapse for calprotectin, TNFi serum levels, and PD score were 3.7 μg/mL, 1.61 μg/mL, and 4, respectively.
The authors concluded that time-to-remission/low disease activity, calprotectin serum levels, TNFi TSL, and PD score were significantly associated with disease relapse. However, only baseline calprotectin serum levels independently predicted disease relapse in RA and PsA patients under TNFi therapy. The study was published on December 13, 2018 in the journal Arthritis Research and Therapy.
Related Links:
University of Barcelona
Biological therapies have dramatically improved the management and prognosis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Remission or low disease activity is possible in an increasing number of patients. Nevertheless, persistent remission is more difficult to achieve since disease relapses are common.
Scientists from the University of Barcelona (Barcelona, Spain) carried out a longitudinal, prospective, one-year single-center study of 103 patients (47 RA, 56 PsA) receiving TNFi in remission or with low disease activity. All patients underwent clinical assessment at baseline and at 4, 8, and 12 months, including 28-joint swollen and tender joint counts (28-SJC and 28-TJC, respectively), physician and patient global assessment with visual analogue scales (0–100 mm), erythrocyte sedimentation rate (ESR; mm), and C-reactive protein (CRP; mg/dL).
Calprotectin serum levels, TNFi trough serum levels, and antidrug antibodies were determined at baseline (visit 0) and during disease relapse using an enzyme-linked immunosorbent assay (ELISA) test kit Calprolab, calprotectin ELISA (ALP), and Promonitor, respectively. To reduce variations in calprotectin determinations, the whole procedure was performed in a Triturus autoanalyzer. Additionally, serum samples were collected at 4, 8, and 12 months of follow-up to assess longitudinal changes in drug trough serum levels.
The scientists reported that 95 patients completed one year of follow-up, of whom 12 experienced a relapse. At baseline, relapsers had higher calprotectin levels, lower TNFi TSL, and higher power Doppler (PD) activity than nonrelapsers. Receiver operating characteristic (ROC) analysis showed calprotectin fully predicted relapse (area under the curve (AUC) = 1.00). The cut-off levels determined by ROC analysis for the optimal prediction of relapse for calprotectin, TNFi serum levels, and PD score were 3.7 μg/mL, 1.61 μg/mL, and 4, respectively.
The authors concluded that time-to-remission/low disease activity, calprotectin serum levels, TNFi TSL, and PD score were significantly associated with disease relapse. However, only baseline calprotectin serum levels independently predicted disease relapse in RA and PsA patients under TNFi therapy. The study was published on December 13, 2018 in the journal Arthritis Research and Therapy.
Related Links:
University of Barcelona
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms